Ultimovacs ASA (STU:7UM)
€ 0.2045 0 (0%) Market Cap: 7.12 Mil Enterprise Value: -3.75 Mil PE Ratio: 0 PB Ratio: 0.44 GF Score: 20/100

Ultimovacs ASA to Discuss the NIPU Study Results Call Transcript

Oct 31, 2023 / 01:00PM GMT
Carlos de Sousa
Ultimovacs ASA - CEO

Good afternoon, everybody, and welcome to the Ultimovacs webcast. During this webcast, we will be talking about the results from the NIPU trial that was just recently presented at ESMO, but also a little bit about the press release we had this morning on our second trial, the INITIUM trial, and some of the changes we implemented there.

As you all know, we had some, like many other companies in Madrid, had problems with a lot of streaming due to the bandwidth. So we are taking this opportunity to address some of the topics that we covered there, but also take the opportunity to talk about some of the questions -- the topics that we have been receiving so far.

So I have to say that these are very, very exciting times for cancer patients, but also for companies working in the space of cancer vaccines. We have now two companies that, for the first time, have shown in randomized competitive trials that cancer vaccines work. One of those companies, Moderna, with their individualized vaccine, has shown that in a study that they did in melanoma patients,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot